Sirna Therapeutics Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sirna Therapeutics Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: A.J. Mullen	1/8/2009 12:06:24 PM
	of 562

SILENCE THERAPEUTICS PLC: Research Update Silence Therapeutics plc Silence Therapeutics' partner Quark initiates next stage of clinical trials on DGF prevention drug developed using Silence's chemistry London - 8 January 2009 - Silence Therapeutics, the leading European biopharmaceutical company focused on RNA interference, is pleased to report that its partner Quark Pharmaceuticals Inc. has initiated Phase I/II clinical trials of a drug based on Silence's proprietary chemistry called AtuRNAi. Quark has today announced that QPI-1002 - its small interfering RNA (siRNA) drug targeting the p53 gene - has entered Phase I/II clinical trials for the prevention of delayed graft function (DGF) in deceased donor adult kidney transplant patients. QPI-1002, previously known as DGFi, incorporates Silence's AtuRNAi technology. Iain Ross, chairman and chief executive, said: "Silence is delighted that Quark Pharmaceuticals has been able to advance QPI-1002 into clinical trials for DGF. We believe this provides further validation of Silence's AtuRNAi technology." Ends Enquiries: For further information, please contact the following: Silence Therapeutics plc Powerscourt +44(0)20 7307 1620 +44(0)20 7250 1446 Iain Ross, Chairman & CEO Paul Durman

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext